Injectable Monthly Buprenorphine 101

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • CPE: 1.00
    • ASWB ACE: 1.00
    • CNE: 1.00
  • Cost: Free
  • Release: Feb 7, 2022
  • Expires: Dec 6, 2024
  • Estimated Time to Complete:
    1 Hour(s)
  • Average User Rating:
    ( Ratings)

Injectable Monthly Buprenorphine 101 enduring module is a recording from the live Regularly Scheduled Series dated June 3, 2021. If you claimed credit for this session at the live meeting, you should not claim credit for this module.

Faculty

Michelle R.  Lofwall Michelle R. Lofwall, MD, DFASAM
Professor
Psychiatry and Behavioral Science
Center on Drug and Alcohol Research
University of Kentucky College of Medicine
Bell Alcohol and Addictions Chair and Medical Director
First Bridge Clinic
UK HealthCare
Lexington, Kentucky

Laura K.  Stinson Laura K. Stinson, PharmD
Academic Detailing Pharmacist,
Kentucky HEALing Communities Study
University of Kentucky
Lexington, Kentucky

Needs Statement

Individuals with OUD need more treatment options that can address problems such as: nonadherence, medication misuse/diversion/theft, access to care, and transportation limitations. Injectable monthly buprenorphine may help address several of the limitations associated with transmucosal buprenorphine. Healthcare providers, social workers, and others involved in the care of individuals with OUD need to be familiar with injectable monthly buprenorphine, the unique requirements for obtaining and administering it, and the REMS requirements to ensure its efficacy and patient safety

Target Audience

Physicians, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Social Workers

Objectives

Upon completion of this activity, participants will be able to:

  • Identify individuals who would be appropriate candidates for injectable monthly buprenorphine and those who should not receive this treatment
  • Explore published studies and data related to injectable monthly buprenorphine
  • List the required steps for the two methods of obtaining injectable monthly buprenorphine 
  • Describe the dosage, administration, and adverse effects of injectable monthly buprenorphine

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Practice-based learning and improvement
  • Interpersonal and communication skills
  • Professionalism
  • Systems-based practice

IPE Competencies

  • Values/Ethics for Interprofessional Practice
  • Roles/ Responsibilities
  • Interprofessional Communication
  • Teams and Teamwork

CPE
This -based activity will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.00 general continuing education credit.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. 

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

In collaboration with UK Substance Use Research Priority Area.